Chimeric antigen receptor T cell immunotherapy in advanced gastric cancer:research progress
10.16781/j.CN31-2187/R.20230501
- VernacularTitle:嵌合抗原受体T细胞免疫疗法在晚期胃癌中的应用进展
- Author:
Hao WANG
1
;
Zhengxing LI
;
Tianhang LUO
Author Information
1. 海军军医大学(第二军医大学)第一附属医院胃肠外科,上海 200433
- Keywords:
stomach neoplasms;
immunotherapy;
chimeric antigen receptor T cell;
claudin 18.2;
natural killer cell group 2 member D;
epithelial cell adhesion molecule
- From:
Academic Journal of Naval Medical University
2024;45(11):1336-1342
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer(GC)is one of the most common malignant tumors,and most GC patients in China are diagnosed as progressive GC at their first visit and late stage patients fail to have surgical treatment.The effects of conventional treatments,including chemotherapy,radiotherapy and targeted therapy,are limited and may induce poor prognosis.As a new treatment in hematological malignancy,chimeric antigen receptor(CAR)-T cell(CAR-T)immunotherapy is indicated as a promising treatment for advanced GC,which paves a new way for the GC immunotherapy.However,there are still some obstacles to overcome,such as the heterogeneity of GC,immunosuppression of tumor microenvironment,tumor target antigen escape and off-target toxicity.In this review,the CAR structure,therapeutic principle of CAR-T,and the main targets and treatment status of CAR-T immunotherapy for advanced GC are reviewed;the challenges faced by CAR-T immunotherapy in GC are discussed,so as to provide new ideas for the clinical immunotherapy of advanced GC.
